(Q54446563)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20070321%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Molecular detection of epidermal growth factor receptor in colorectal cancer: does it still make sense? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20070321%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20070321%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Margherita Nannini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20070321%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Maria A Pantaleo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20070321%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Giulia Piazzi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20070321%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

P Paterini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20070321%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

S La Rovere

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20070321%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

A Maleddu

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20070321%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

G Biasco

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20070321%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

1 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20070321%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20070321%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20070321%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

542-548

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20070321%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20070321%20AND%20SRC:MED&resulttype=core&format=json

The EGFR as a target for anticancer therapy--focus on cetuximab

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Molecular determination of epidermal growth factor receptor in normal and neoplastic colorectal mucosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Molecular determinants of cetuximab efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

EGFR, HER-2 and COX-2 levels in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X

Nuclear Factor-kB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1318.2010.02212.X